Federico Fantaguzzi

Federico Fantaguzzi

Auto-generated profile, based on publicly available information

Federico Fantaguzzi

School of Medicine, Vita-Salute San Raffaele University, Milan, Italy

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2022 in Retina
Verified
Journal Article
Closed access
RSRiccardo Md Sacconi
Riccardo Md Sacconi
PFPaolo Forte
Paolo Forte
VCVittorio Capuano
Vittorio Capuano
Alexandra MiereAlexandra Miere
Alexandra Miere
ECEliana Costanzo
Eliana Costanzo
GQGiuseppe Querques
Giuseppe Querques
Purpose: To investigate fellow eyes of newly diagnosed unilateral exudative Type 3 (T3) macular neovascularization (MNV) patients by assessing the presence and progression of a preclinical neovascular component during a 3-year follow-up. Methods: This is a longitudinal study involving three retinal referral centers. Patients affected by unilateral exudative treatment-naive T3 MNV were enrolled. Results: Twenty-four eyes of 24 patients (79 ± 6 years old) were enrolled. Nine eyes (37%) displayed a nonexudative T3 MNV at baseline that developed exudation after a mean of 9 ± 9 months. Fifteen eyes that did not display a nonexudative Type 3 MNV at baseline. Five eyes (21%) did not display neovessels at baseline, but showed a nonexudative T3 after 13 ± 9 months, and exudation after 8 ± 3 months. Five eyes (21%) developed active exudative T3 MNV after 23 ± 9 months, with no detectable nonexudative stage at baseline. Five eyes (21%) did not show MNV, but progressed to geographic atrophy by 36 months of follow-up. Overall, T3 MNV in the fellow eye accounted for 79%, all developing exudation over 3 years of follow-up. Conclusion: The occurrence of a nonexudative T3 MNV is a frequent event in the fellow eye of patients newly diagnosed with unilateral exudative T3 MNV and it precedes the development of exudation over 3 years (prevalence of 37% and cumulative incidence of 79%). Optical coherence tomography angiography approach may be used to perform an early diagnosis and treatment of patients with T3 MNV.

5 January 2024 in Ophthalmology and Therapy
Verified
Journal Article
Open access
PDF file
BTBeatrice Tombolini
Beatrice Tombolini
ECEmanuele crincoli
Emanuele crincoli
RSRiccardo Sacconi
Riccardo Sacconi
MBMarco Battista
Marco Battista
FFFederico Fantaguzzi
Federico Fantaguzzi
GQGiuseppe Querques
Giuseppe Querques
Optical coherence tomography angiography (OCTA) has extensively enhanced our comprehension of eye microcirculation and of its associated diseases. In this narrative review, we explored the key concepts behind OCTA, as well as the most recent evidence in the pathophysiology of age-related macular degeneration (AMD) made possible by OCTA. These recommendations were updated since the publication in 2020, and are targeted for 2023. Importantly, as a future perspective in OCTA technology, we will discuss how artificial intelligence has been applied to OCTA, with a particular emphasis on its application to AMD study.